Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial

Overview of attention for article published in Critical Care, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs: 1 blog

twitter: 15 X users

Citations

dimensions_citation: 65 Dimensions

Readers on

mendeley: 68 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 18 X posts from 15 X users, with an upper bound of 113,607 followers.

Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial https://t.co/fEUe1YGGGm

Reply Repost Favourite

RT @ISICEM: @ISICEM Critical Care input: Treatment of #COVID19-associated #ARDS with mesenchymal stromal cells: a multicenter randomized do…

Reply Repost Favourite

Am sad stem cells for ARDS didn’t work (the rationale is clever) but also feel like our understanding of fundamental biology is still very lacking so we find translational therapy hard https://t.co/t08sC97tEs

Reply Repost Favourite

RT @Crit_Care: #CritCare #OpenAccess #COVID19: #Umbilical cord-derived #mesenchymal #stromal #cells have potentially immune-modulatory prop…

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 14 additional X posts.